The experimental drug teplizumab shows promise for blocking the advance of type 1 diabetes in its earliest stages.

The results of a Phase 2 study show this new agent was strikingly effective over a period of two years in about half of the patients participating in the trial.

Continue Reading

John Schieszer has the latest on the study findings in today’s Medical Minute.

Topics:

Diabetes